The DOI matches its Crossref record.
Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal
Abstract
Nineteen heroin-dependent male volunteers were administered buprenorphine sublingually, in ascending daily doses of 2, 4, and 8 mg. They were maintained on 8 mg daily through study day 18. On study days 19 through 36, subjects in group 1 continued to receive burprenorphine daily; subjects in group 2 received buprenorphine or placebo on alternate days. On days 37 through 52, all subjects received placebo. Subjects receiving buprenorphine on alternate days reported significantly greater urge for an opioid, increased dysphoria scores, and pupillary dilation on placebo days. After abrupt termination of buprenorphine, no withdrawal signs were detected with the Himmelsbach scale. However, subjects reported mild-to-moderate opioid withdrawal symptoms, peaking at 3 to 5 and lasting for 8 to 10 days. Daily administration of buprenorphine provided greater control of subtle opioid withdrawal symptoms, but subjects could tolerate a between-dose interval of 48 hours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Addiction motivation reformulated: an affective processing model of negative reinforcement
Baker, T. B., Piper, M. E., McCarthy, D. E., Majeskie, M. R., & Fiore, M. C. (2004) · Psychological Review · doi:10.1037/0033-295x.111.1.33 · Cited by 2,162
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Self-citationConnock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 585
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480200058024 · Cited by 572
Self-citationBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Craving's place in addiction theory: Contributions of the major models
Skinner, M. D., & Aubin, H.-J. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.024 · Cited by 372
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R., Kimber, J., Breen, C., & Davoli, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub2 · Cited by 360
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346
Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300251 · Cited by 320
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent
Compton, P., Charuvastra, V. C., & Ling, W. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00200-3 · Cited by 311
Buprenorphine vs Methadone Maintenance Treatment for Concurrent Opioid Dependence and Cocaine Abuse
Schottenfeld, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200041006 · Cited by 303
Buprenorphine for the management of opioid withdrawal
Gowing, L., Ali, R., & White, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002025.pub4 · Cited by 297
Jones, H. E., Johnson, R. E., Jasinski, D. R., O’Grady, K. E., Chisholm, C. A., Choo, R. E., Crocetti, M., Dudas, R., Harrow, C., Huestis, M. A., et al. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.11.013 · Cited by 295
Self-citationBuprenorphine: Considerations for Pain Management
Johnson, R. E., Fudala, P. J., & Payne, R. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.005 · Cited by 290
Self-citationHuman Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine
Kuhlman, J. J., Lalani, S., Magluilo, J., Levine, B., Darwin, W. D., Johnson, R. E., & Cone, E. J. (1996) · Journal of Analytical Toxicology · doi:10.1093/jat/20.6.369 · Cited by 273
Self-citationAre detoxification programmes effective?
Mattick, R. P., & Hall, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90215-9 · Cited by 196
Greenwald, M. K., Comer, S. D., & Fiellin, D. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.07.035 · Cited by 174
Office-Based Treatment of Opioid-Dependent Patients
Fiellin, D. A., & O'Connor, P. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp013579 · Cited by 148
Greenwald, M., Johanson, C.-E., Bueller, J., Chang, Y., Moody, D. E., Kilbourn, M., Koeppe, R., & Zubieta, J.-K. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.043 · Cited by 124
Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes
Johnson, R. E., Jones, H. E., Jasinski, D. R., Svikis, D. S., Haug, N. A., Jansson, L. M., Kissin, W. B., Alpan, G., Lantz, M. E., Cone, E. J., et al. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00194-0 · Cited by 125
Self-citationBuprenorphine tapering schedule and illicit opioid use
Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., Jenkins, J., Hasson, A., Annon, J., Saxon, A., et al. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02455.x · Cited by 112
Dunn, K. E., Sigmon, S. C., Strain, E. C., Heil, S. H., & Higgins, S. T. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.05.033 · Cited by 65
“This may be related to buprenorphine’s long plasma half-life and slow dissociation from the receptor (Bickel et al., 1988a; Bullingham et al., 1980; Fudala et al., 1990; Hambrook and Rance, 1976; Jasinski et al., 1978).”
BackgroundResultInfluentialSokol, R., Albanese, M., Chew, A., Early, J., Grossman, E., Roll, D., Sawin, G., Wu, D. J., & Schuman-Olivier, Z. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0176-y · Cited by 14
Buprenorphine for Opioid Detoxification: A Brief Review
Kosten, T. R. (2003) · Addictive Disorders & Their Treatment · doi:10.1097/00132576-200302040-00001 · Cited by 8
Metadata
- Authors
- Fudala, P. J., Jaffe, J. H., Dax, E. M., & Johnson, R. E.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1990-04
- Volume
- 47
- Issue
- 4
- Pages
- 525-534
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2061161214
- Cited by
- 191
- References
- 0
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.